Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, ...

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...

The market is responding to this breakthrough. Analysts at Exactitude Consultancy predict that the global immunotherapy ...

Adjuvant Chemotherapy for Stage II Colorectal Cancer: Can Pooled Analyses Compensate? Despite an increasing number of stage II compared with stage III patients attending oncology clinics (the ...

1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. 2Medical Faculty, University Duisburg-Essen, Essen, Germany. 3National Center of Tumor Diseases ...

This mini-review highlights the latest advancements in tumor immunotherapy, with a focus on cellular therapies, and addresses the resistance mechanisms that hinder their effectiveness in lung and ...

3 An important clinical rationale for the use of adjuvant pelvic radiotherapy is the fact that peri-operative chemotherapy and immunotherapy have been shown to reduce the rates of distant disease ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society ...

Dec. 23, 2024 — A research team has developed a groundbreaking technology that can treat colon cancer by converting cancer cells into a state resembling normal colon cells without killing them ...

Keytruda has been approved by the FDA as a surgery-spanning immunotherapy in this group ... the INTerpath-002 study of the combination as adjuvant therapy for patients with stage 2 to 3b NSCLC ...